Get the Daily Brief
Latest Biotech News
Walgreens Clinical Trials Effort Boosts Patient Enrollment by 20%
Since launching a dedicated clinical trials unit, Walgreens has approached over 17 million individuals about participating in drug studies, resulting in a 20% higher enrollment rate compared to...
Thermo Fisher Scientific Opens Carbon Neutral Manufacturing Center in North Carolina
Thermo Fisher Scientific inaugurated a 375,000-square-foot carbon-neutral manufacturing facility in Mebane, North Carolina, poised to produce over 40 million laboratory pipette tips weekly. This...
Lilly’s Oral GLP-1 Pill Advances Obesity and Diabetes Treatment
Eli Lilly announced readiness to file for FDA approval of orforglipron, an oral GLP-1 receptor agonist shown in a Phase 3 trial to significantly reduce body weight and improve glycemic control in...
Regeneron Boosts Rare Disease Pipeline with siRNA Therapy Win
Regeneron reported positive Phase 3 results for an siRNA-based drug licensed from Alnylam, targeting an under-the-radar rare autoimmune condition. This success positions Regeneron to pursue FDA...
Akeso Scores Dual Phase 3 Wins in Autoimmune Conditions
Chinese biotech Akeso Pharmaceuticals announced successful completion of Phase 3 trials for two monoclonal antibodies: gumokimab in ankylosing spondylitis and manfidokimab in moderate to severe...
Ribomic Advances Umedaptanib to Phase III for Achondroplasia
Ribomic is set to initiate Phase III trials for umedaptanib pegol (RBM-007), an oligonucleotide aptamer targeting anti-fibroblast growth factor 2 to treat achondroplasia. The therapy shows...
Biotech Royalty Deal: BeOne Sells Amgen Imdelltra Revenues
BeOne Medicines (formerly BeiGene) sold its worldwide royalty rights outside China for Imdelltra (tarlatamab) sales to Royalty Pharma for an upfront of approximately $885 million, with a total...
FDA Suspends Valneva’s Chikungunya Vaccine License Amid Safety Concerns
The U.S. FDA suspended the biologics license for Valneva’s chikungunya vaccine Ixchiq following reports of serious adverse events consistent with chikungunya-like illness. The agency ordered an...
AbbVie’s $1.2 Billion Bet on Gilgamesh’s Psychedelic for Depression
AbbVie announced acquisition of psychedelic drug candidate bretisilocin from Gilgamesh Pharmaceuticals for up to $1.2 billion, strengthening AbbVie's growing neuroscience portfolio. The asset is...
Pioneering Pig-to-Human Lung Xenotransplant Maintains Function Nine Days
In a pioneering procedure, a genetically modified pig lung was successfully transplanted into a brain-dead human patient, surviving and functioning for nine days without hyperacute rejection....
Walgreens Boosts Clinical Trial Enrollment via Community-Based Outreach
Walgreens has approached over 17 million individuals through its clinical trials unit, increasing trial enrollment likelihood by 20% compared to traditional recruitment methods. Their...
NASA’s JUNO Completes Liquid Filling, Begins Data Acquisition
The Jiangmen Underground Neutrino Observatory (JUNO) marked a critical milestone by completing the filling of its 20,000-ton liquid scintillator detector. This step activates the experiment’s data...
AbbVie’s $1.2B Psychedelic Drug Acquisition Boosts Neuroscience Pipeline
AbbVie has intensified its focus on neuroscience by acquiring Gilgamesh Pharmaceuticals’ investigational psychedelic drug candidate, bretisilocin, for up to $1.2 billion. This acquisition builds...
Valneva’s Chikungunya Vaccine License Suspended by FDA Amid Safety Concerns
The FDA has suspended the U.S. license for Valneva's chikungunya vaccine, Ixchiq, following new reports of serious adverse events including chikungunya-like illnesses in vaccinated individuals....
Pioneering Pig-to-Human Lung Transplant Shows Nine-Day Functionality
A landmark xenotransplantation achievement has been reported with the first genetically modified pig lung transplant functioning in a brain-dead human recipient for nine days. The procedure...
Eli Lilly’s Oral GLP-1 Orforglipron Shows Weight Loss, Glycemic Control in Phase 3
Eli Lilly’s investigational oral GLP-1 receptor agonist orforglipron achieved significant weight loss and blood sugar reductions in obese patients with type 2 diabetes during a 72-week Phase 3...
Sarepta’s DMD Gene Therapy Elevidys Shows Improved Safety in Ambulatory Patients
Sarepta Therapeutics released updated safety data for Elevidys, its gene therapy for Duchenne muscular dystrophy, reporting zero ambulatory deaths related to acute liver failure among over 1,000...
Walgreens’ Clinical Trials Unit Boosts Patient Enrollment by 20%
Walgreens has engaged over 17 million people in clinical trial outreach, reporting that patients contacted through its clinical trials business are 20% more likely to enroll compared to...
AI-Powered Tools Accelerate Cell Tracking and Cancer Tissue Analysis
New AI-driven tools have been developed to enhance biological research and diagnostics. Ultrack, an integrated deep learning model, enables scalable and accurate real-time tracking of cell...
Significant Shift as NCI Ends Pediatric Brain Tumor Consortium Funding
The National Cancer Institute will cease funding the 26-year-old Pediatric Brain Tumor Consortium, redirecting resources towards the broader Children's Oncology Group Pediatric Early Phase...